{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:17:13Z","timestamp":1776089833865,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00535-022-01850-2","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T13:03:08Z","timestamp":1643720588000},"page":"133-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-0263","authenticated-orcid":false,"given":"Soichiro","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Toyokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kuwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Esaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Demura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitoshi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Mabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"key":"1850_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","volume":"44","author":"F Yasuhiro","year":"2009","unstructured":"Yasuhiro F, Tetsuo A. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518\u201334.","journal-title":"J Gastroenterol"},{"key":"1850_CR2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751\u201367.","journal-title":"J Gastroenterol"},{"key":"1850_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium- competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u201348.","journal-title":"Aliment Pharmacol Ther"},{"key":"1850_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"1850_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3164\/jcbn.18-75","volume":"64","author":"S Miyamoto","year":"2019","unstructured":"Miyamoto S, Tsuda M, Kato M, et al. Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test. J Clin Biochem Nutr. 2019;64:174\u20139.","journal-title":"J Clin Biochem Nutr"},{"key":"1850_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/apt.15062","volume":"49","author":"T Oshima","year":"2019","unstructured":"Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:140\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"1850_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"1850_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"1850_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","volume":"69","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69:224\u201330.","journal-title":"Gut"},{"key":"1850_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95:156\u201361.","journal-title":"Digestion"},{"key":"1850_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1756283X17705329","volume":"10","author":"K Iwakiri","year":"2017","unstructured":"Iwakiri K, Sakurai Y, Shiino M, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 2017;10:439\u201351.","journal-title":"Therap Adv Gastroenterol"},{"key":"1850_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.bpg.2010.09.004","volume":"24","author":"SB de Varannes","year":"2010","unstructured":"de Varannes SB, Coron E, et al. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24:905\u201321.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1850_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1440-1746.2008.05644.x","volume":"24","author":"S Ono","year":"2009","unstructured":"Ono S, Kato M, Ono Y, et al. Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sohadium following initial administration and reintroduction: a randomized, cross-over study using wireless pH monitoring capsules. J Gastroenterol Hepatol. 2009;24:639\u201345.","journal-title":"J Gastroenterol Hepatol"},{"key":"1850_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000485795","volume":"97","author":"M Umezawa","year":"2018","unstructured":"Umezawa M, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis. Digestion. 2018;97:309\u201315.","journal-title":"Digestion"},{"key":"1850_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10388-018-00654-9","volume":"16","author":"Y Hoshikawa","year":"2019","unstructured":"Hoshikawa Y, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus. 2019;16:201\u20136.","journal-title":"Esophagus"},{"issue":"5","key":"1850_CR16","doi-asserted-by":"publisher","first-page":"e000197","DOI":"10.1136\/bmjgast-2017-000197","volume":"16","author":"M Kato","year":"2018","unstructured":"Kato M, Ito N, Demura M, et al. Study for every other day administration of vonoprazan in maintenance treatment of erosive GERD: study protocol for a multicentre randomised cross-over study. BMJ Open Gastroenterol. 2018;16(5):e000197.","journal-title":"BMJ Open Gastroenterol"},{"key":"1850_CR17","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u201320.","journal-title":"Am J Gastroenterol"},{"key":"1850_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","volume":"39","author":"M Kusano","year":"2004","unstructured":"Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888\u201391.","journal-title":"J Gastroenterol"},{"key":"1850_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF01535722","volume":"33","author":"J Svedlund","year":"1988","unstructured":"Svedlund J, Sjodin I, Dotevall G, et al. GSRS\u2013a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129\u201334.","journal-title":"Dig Dis Sci"},{"key":"1850_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-6-12","volume":"6","author":"KR Kulich","year":"2008","unstructured":"Kulich KR, Madisch A, Pacini F, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008;6:12.","journal-title":"Health Qual Life Outcomes"},{"key":"1850_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00365521.2013.878380","volume":"49","author":"A Nagahara","year":"2014","unstructured":"Nagahara A, Hojo M, Asaoka D, et al. A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan. Scand J Gastroenterol. 2014;49:409\u201317.","journal-title":"Scand J Gastroenterol"},{"key":"1850_CR22","first-page":"1","volume":"8","author":"E Savarino","year":"2016","unstructured":"Savarino E, Martinucci I, Furnari M, et al. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2016;8:1\u20139.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1850_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000028183","volume":"56","author":"W Kromer","year":"1998","unstructured":"Kromer W, Kruger U, Huber R, et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56:57\u201370.","journal-title":"Pharmacology"},{"key":"1850_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-comparative acid blocker, with lansoprazole in animals. J Pharmacol Exper Ther. 2011;337:797\u2013804.","journal-title":"J Pharmacol Exper Ther"},{"key":"1850_CR25","first-page":"213","volume":"32","author":"S Yuuichi","year":"2017","unstructured":"Yuuichi S, Yuki N, et al. Challenges and future of acid secretion suppression therapy Carcinoid. Rinsyou syoukakinaika. 2017;32:213\u20138.","journal-title":"Rinsyou syoukakinaika"},{"key":"1850_CR26","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.3390\/ijms20205128","volume":"20","author":"L Lee","year":"2019","unstructured":"Lee L, Irene RA, Tetsushige I, et al. Insights into effects\/risks of chronic hypergastrinemia and lifelong ppi treatment in man based on studies of patients with Zollinger-ellison syndrome. Int J Mol Sci. 2019;20:5128.","journal-title":"Int J Mol Sci"},{"key":"1850_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17745776","author":"K Sugano","year":"2018","unstructured":"Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018. https:\/\/doi.org\/10.1177\/1756283X17745776.","journal-title":"Therap Adv Gastroenterol"},{"key":"1850_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00228-017-2324-1","volume":"74","author":"T Suzuki","year":"2018","unstructured":"Suzuki T, Kagami T, Uotani T, et al. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol. 2018;74:45\u201352.","journal-title":"Eur J Clin Pharmacol"},{"key":"1850_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000484217","volume":"97","author":"Y Kojima","year":"2018","unstructured":"Kojima Y, Takeuchi T, Sanomura M, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study. Digestion. 2018;97:70\u20135.","journal-title":"Digestion"},{"key":"1850_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","volume":"81\u201382","author":"Y Kinoshita","year":"2016","unstructured":"Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp. 2016;81\u201382:1\u20137.","journal-title":"Curr Ther Res Clin Exp"},{"key":"1850_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00535-019-01609-2","volume":"54","author":"Y Yokoya","year":"2019","unstructured":"Yokoya Y, Ataru I, Akihiro U, et al. Cost-utility analysis of a \u201cvonoprazan-first\u201d strategy versus \u201cesomeprazole- or rabeprazole-first\u201d strategy in GERD. J Gastroenterol. 2019;54:1083\u201395.","journal-title":"J Gastroenterol"},{"key":"1850_CR32","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.2169\/internalmedicine.2535-18","volume":"58","author":"H Yasuki","year":"2019","unstructured":"Yasuki H. Vonoprazan versus lansoprazole for the initial treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. Intern Med. 2019;58:2427\u201333.","journal-title":"Intern Med"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01850-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-022-01850-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01850-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T13:10:50Z","timestamp":1646140250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-022-01850-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1007\/s00535-022-01850-2","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}